Nexus Uranium Corp. closed a non-brokered unit offering, raising $1.92 million by issuing common shares and warrants exercisable at $0.70 until April 2028. The proceeds will support advancing uranium projects in South Dakota and Arizona and general corporate purposes. Insiders participated in the offering, and the company granted 600,000 deferred share units to directors, officers, and consultants, vesting over one year. Nexus also engaged HoldCo Markets Advisory for equity research and social media services to enhance market presence.
Nexus Uranium's recent financing announcement provides context for readers following the Basic Materials sector. For readers following Basic Materials stocks, here is Pluang's market snapshot as of Oct 19, 2026 20:31 WIB: out of 83 priced US stocks, 51 rose and 28 fell. Notable movers include Element Solutions Inc. (ESI) at USD 35.62 with a 1.61% increase and a typical hold time of 10 days, ArcelorMittal SA (MT) at USD 64.05 with a 1.59% increase and a typical hold time of 36 days, and Solstice Advanced Materials Inc. (SOLS) at USD 60.00 with a 1.27% increase and a typical hold time of 4 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
